title: ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter].
authors.affiliation: Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK. david.matthews@ocdem.ox.ac.uk.|National Institute for Health Research (NIHR), Oxford Biomedical Research Centre, Oxford, UK. david.matthews@ocdem.ox.ac.uk.|Harris Manchester College, University of Oxford, Mansfield Road, Oxford, UK. david.matthews@ocdem.ox.ac.uk.
authors.forename: D R
authors.initials: DR
authors.lastname: Matthews
authors.affiliation: Section of Endocrinology, Yale University School of Medicine and Yale-New Haven Hospital, New Haven, CT, USA.
authors.forename: S E
authors.initials: SE
authors.lastname: Inzucchi
mesh_terms: D000465:Algorithms; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D057285:Precision Medicine / Q000639:trends*; D012955:Societies, Medical / Q000639:trends*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D008687:Metformin